Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.130
+0.060 (1.95%)
May 19, 2025, 4:00 PM - Market closed
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
659.46M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SVRA News
- 1 day ago - Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - Business Wire
- 6 days ago - Savara Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 7 days ago - Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference - Business Wire
- 18 days ago - Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire
- 4 weeks ago - Savara: Make-It-Or-Break-It Molbreevi BLA Filing - Seeking Alpha
- 5 weeks ago - Savara Announces New Employment Inducement Grant - Business Wire
- 6 weeks ago - Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - Business Wire
- 7 weeks ago - Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Business Wire